LIS22 / Xenothera - LARVOL DELTA

LIS22: AN EFFECTIVE MULTIMODAL POLYCLONAL ANTIBODY TARGETING T-CELL MALIGNANCIES (ICML 2025) - "LIS22 efficacy in vivo were evaluated in NMRI nude mice and SRG rats using T1301 and Jurkat cancer cell lines...In both CDC and apoptosis cytotoxicity assays, LIS22 displayed a significantly higher potency on T cell blood cancers and no toxicity on healthy blood cells compared to Alemtuzumab (Anti-CD52) and Belinostat (HDAC inhibitor)... LIS22 has emerged as a novel and promising antibody for the treatment of T-cell hematologic malignancies. It is currently under clinical investigation (Phase I/II) for the treatment of peripheral T-cell lymphoma (PTCL)."

Lymphoma • Oncology • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma

PALT TRIAL: FIRST IN CLASS GLYCO-HUMANIZED POLYCLONAL ANTIBODY DIRECTED AGAINST TUMORAL T CELLS, IN PATIENTS WITH RELAPSED/REFRACTORY PERIPHERAL T CELLS LYMPHOMA (ICML 2025) - P1/2 | "Background: LIS22 is a first in class glyco-humanized polyclonal antibody (GH-pAb) targeting selectively and simultaneously multiple tumor-associated malignant T-cell antigens... Accrual is ongoing in this first in human trial"

Clinical • Hematological Malignancies • Hepatosplenic T-cell Lymphoma • Lymphoma • Oncology • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma

LIS22, a first in class polyclonal antibody immunotherapy in T cell blood cancers (AACR 2024) - "LIS22 efficacy in vivo were evaluated in NMRI nude mice and SRG rats using T1301 and Jurkat cancer cell lines...In both CDC and apoptosis cytotoxicity assays, LIS22 displayed a significantly higher potency on T cell blood cancers and no toxicity on healthy blood cells compared to PTCL clinically active drug Alemtuzumab (Anti-CD52)... LIS22 appeared as a novel and promising cancer immunotherapy against T Cell hematologic malignancies. It has already been administered to human in another indication and showed a satisfactory PK and safety profile (no signs of immunotoxicity or systemic cytokine release). LIS22 is now ready to enter Phase I/II in the coming months for the treatment of peripheral T cell lymphoma (PTCL)."

Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma

Orphan Designation: Treatment of T-cell lymphoma (FDA) - Date Designated: 08/07/2023

Orphan drug • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma

Orphan Designation: Treatment of idiopathic pulmonary fibrosis (FDA) - Date Designated: 08/09/2023

Orphan drug • Idiopathic Pulmonary Fibrosis • Respiratory Diseases